Please login to the form below
Donanemab
This page shows the latest Donanemab news and features for those working in and with pharma, biotech and healthcare.
Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
Trial will evaluate donanemab in participants at risk for cognitive and functional decline related to Alzheimer’s. ... Donanemab is also being studied in the ongoing phase 3 TRAILBLAZER-ALZ 2 study in early symptomatic Alzheimer’s disease patients.
Latest news
-
Breakthrough therapy designated for Lilly’s investigational Alzheimer’s drug donanemab
The US Food and Drug Administration (FDA) has granted Eli Lilly’s investigational Alzheimer’s disease drug donanemab a breakthrough therapy designation (BTD). ... The study enrolled a total of 257 patients, with 131 assigned to receive donanemab and
-
Lilly to expand donanemab study in a bid for approval in Alzheimer’s disease
this did not translate to statistical significance between the donanemab-treated and placebo groups. ... The study enrolled a total of 257 patients, with 131 assigned to receive donanemab and 126 to receive placebo.
-
Lilly’s anti-amyloid antibody donanemab renews Alzheimer’s hopes
Drug demonstrated a 'significant' slowing of cognitive decline. Eli Lilly’s amyloid-targeting antibody donanemab has shown promise in the treatment of Alzheimer’s disease, sending its stocks soaring and renewing ... function’. In other measures,
-
Germany’s Vivoryon raises €43m for Alzheimer’s drug trial
Eli Lilly is developing an antibody drug against it – called donanemab – which has reached the phase 2 testing stage.
-
Eli Lilly shutters UK neuroscience unit, with 80 job losses expected
Its pipeline currently includes solanezumab for Alzheimer’s – which has already failed earlier phase 3 trials – along with two antibodies for the disease in mid-stage testing (donanemab and zagotenemab) and
Breakthrough therapy designated for Lilly’s investigational Alzheimer’s drug donanemab
Germany’s Vivoryon raises €43m for Alzheimer’s drug trial
Eli Lilly shutters UK neuroscience unit, with 80 job losses expected
More from news
Approximately 4 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Alzheimer’s: the search for a cure
Recently published study results for aducanumab and donanemab, both antibodies against amyloid, showed effects that indicated some improvement in cognition and daily function in patients with early Alzheimer’s. ... In the aforementioned aducanumab and
Alzheimer’s: the search for a cure
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
-
Events Executive
-
Depending on Experience
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Digital account director
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- Roche engaged in talks with FDA for Alzheimer’s drug candidate
- Pharma’s authentic proof of purpose influences decisions among HCPs and payers
- Merck & Co's cancer drug Keytruda gaining traction in US
- Tyson Fury takes on his Invisible Opponent in hard hitting ad for suicide prevention charity Campaign Against Living Miserably
PMHub
OPEN Health
OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
